Literature DB >> 24060866

Activity of ceftaroline against Enterococcus faecium PBP5.

Xavier Henry1, Oliver Verlaine, Ana Amoroso, Jacques Coyette, Jean-Marie Frère, Bernard Joris.   

Abstract

The opportunistic human pathogen Enterococcus faecium overproduces the low-affinity PBP5. In clinical strains, mutations in PBP5 further reduce its acylation rate by β-lactams. Previous studies have reported that ceftaroline had poor inhibitory activity against β-lactam-resistant E. faecium strains. In this study, we show that ceftaroline exhibits killing activity against our laboratory-derived ampicillin-resistant E. faecium mutant that overproduces a wild-type PBP5 and that ceftaroline inactivates PBP5 much faster than benzylpenicillin and faster than ceftobiprole.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24060866      PMCID： PMC3837919          DOI： 10.1128/AAC.00923-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins.

Authors:  G Zhao; T I Meier; S D Kahl; K R Gee; L C Blaszczak
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs.

Authors:  C Goffin; J M Ghuysen
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

3.  Active-site and membrane topology of the DD-peptidase/penicillin-binding protein no. 6 of Enterococcus hirae (Streptococcus faecium) A.T.C.C. 9790.

Authors:  A el Kharroubi; G Piras; P Jacques; I Szabo; J Van Beeumen; J Coyette; J M Ghuysen
Journal:  Biochem J       Date:  1989-09-01       Impact factor: 3.857

4.  Inhibition of Streptococcus pneumoniae penicillin-binding protein 2x and Actinomadura R39 DD-peptidase activities by ceftaroline.

Authors:  Astrid Zervosen; André Zapun; Jean-Marie Frère
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

5.  Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium.

Authors:  L B Rice; L L Carias; R Hutton-Thomas; F Sifaoui; L Gutmann; S D Rudin
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Authors:  Helio S Sader; Thomas R Fritsche; Koné Kaniga; Yigong Ge; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.

Authors:  P M Small; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 8.  Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics.

Authors:  D J Waxman; J L Strominger
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

Review 9.  Bacterial active-site serine penicillin-interactive proteins and domains: mechanism, structure, and evolution.

Authors:  J M Ghuysen
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

10.  Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium.

Authors:  W Zorzi; X Y Zhou; O Dardenne; J Lamotte; D Raze; J Pierre; L Gutmann; J Coyette
Journal:  J Bacteriol       Date:  1996-08       Impact factor: 3.490
View more
  11 in total

1.  Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.

Authors:  Brian J Werth; Laura M Shireman
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

Review 3.  A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline.

Authors:  Tony K L Kiang; Kyle J Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

Review 4.  Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  Differential Effects of Penicillin Binding Protein Deletion on the Susceptibility of Enterococcus faecium to Cationic Peptide Antibiotics.

Authors:  George Sakoulas; Monika Kumaraswamy; Poochit Nonejuie; Brian J Werth; Micahel J Rybak; Joseph Pogliano; Louis B Rice; Victor Nizet
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

6.  β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Mostafa Aboutaleb; George Sakoulas; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2015-02-01       Impact factor: 5.790

7.  Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions.

Authors:  Razieh Kebriaei; Seth A Rice; Kavindra V Singh; Kyle C Stamper; An Q Dinh; Rafael Rios; Lorena Diaz; Barbara E Murray; Jose M Munita; Truc T Tran; Cesar A Arias; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 8.  β-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis.

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

9.  Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Authors:  Jordan R Smith; Juwon Yim; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 10.  Reversing resistance: The next generation antibacterials.

Authors:  Neel Jayesh Shah
Journal:  Indian J Pharmacol       Date:  2015 May-Jun       Impact factor: 1.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.